Eda Nuhoğlu Kantarcı

Exploring an independent association between rituximab‐cyclophosphamide‐doxorubicin‐vincristine‐prednisolone dose intensity and clinical outcomes in large B‐cell lymphoma: Analyses of subsequent endpoints following a complete response in a real‐world cohort of 1369 patients

Umut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, Elif Birtaş Ateşoğlu et autres

INTRODUCTION: Rituximab-cyclophosphamide-doxorubicin-vincristine-prednisolone (R-CHOP) is a standard first-line treatment in large B-cell lymphoma (LBCL). Dose intensity is frequently reduced because of toxicity or concerns of tolerability. The true impact of such treatment modifications on the response rates is difficult to assess in nonrandomized …

tr (code pays fourni par la source)

A Large Room for Improvement Concerning the Management of Relapsed Refractory Large B-cell Lymphoma in Türkiye: Real-World Outcomes in the Setting Without Access to T-Cell Redirecting Therapies

Umut Yılmaz, Mehmet Sinan Dal, Turgay Ulaş, Elif Birtaş Ateşoğlu et autres

Objectives: Large B-cell lymphoma (LBCL) patients who fail frontline therapy (R/R-LBCL) experience highly unfavorable outcomes.The development of T-cell redirecting therapies is rapidly evolving this outlook.However, costs and infrastructural challenges limit access to such innovative therapies.This study was conducted to document the shortcomings …

tr, kh (code pays fourni par la source)

Retrospective Analysis of Newly Diagnosed Multiple Myeloma Patients with Partial or Worse Response to First-Line Induction Therapy

Fatih Emin Ozturk, Melis Dila Özer Çerme, Eda Nuhoğlu Kantarcı, Damla Ortaboz et autres

Effects of Two Bortezomib-Based Protocols (VCD and VRD) on Responses and Survival as Induction Treatment of Patients with Multiple Myeloma Eligible for Autologous Stem Cell Transplantation

Adnan Nuri Guzel, Melis Dila Özer Çerme, Eda Nuhoğlu Kantarcı, Damla Ortaboz et autres

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Umur Sevket Hatipoglu et autres

Comparative first-line trials in large B-cell lymphoma (LBCL) have mostly failed over the last decade. Failures were commonly attributed to overestimation of the progression risk for the control arms, bringing the precision of the international prognostic index (IPI) into scrutiny. Simplified molecular …

tr, kh (code pays fourni par la source)

664 | SIMPLIFIED MOLECULAR IPI AS ELIGIBILITY CRITERIA FOR CLINICAL TRIALS: ANALYSIS OF THE TURKISH LYMPHOMA STUDY GROUP’S LARGE B‐CELL LYMPHOMA COHORT

Ümit Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Umur Sevket Hatipoglu et autres

patients preferred TTP regimens over FD regimens if it provided a 0.71 percentage-point decrease in grade 3/4 CRS risk, a 12.81 percentage-point decrease in CRS-related hospitalization, a 1.88mo OS increase, or a 2.64 percentage-point increase in the probability of CR at 24 …

tr (code pays fourni par la source)

Perioperative Management of Atypical Hemolytic Uremic Syndrome in a Patient on Maintenance Eculizumab Therapy: A Case Report and Review of the Literature

Aydan Mütiş Alan, Mevlüt Tamer Dinçer, Ata Kaykioğlu, Eda Nuhoğlu Kantarcı et autres

INTRODUCTION: Atypical hemolytic uremic syndrome (aHUS) is a rare, complement-mediated disorder characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury. Eculizumab, a monoclonal antibody that inhibits complement component C5, is a cornerstone therapy for aHUS but increases the risk of infections, …

tr (code pays fourni par la source)

A case with febrile attacks and vasculopathy associated with ADA2 and MEFV pathogenic variants

Kerem Parlar, Eda Tahir Turanlı, Eda Nuhoğlu Kantarcı, Ayşa Hacıoğlu et autres

Deficiency of adenosine deaminase 2 (DADA2), caused by recessive mutations in the adenosine deaminase 2 (ADA2) gene, results in cutaneous or systemic vasculitis with variable clinical manifestations. There is only one other case in literature carrying both ADA2 and MEFV gene pathogenic …

tr (code pays fourni par la source)

Fine‐tuning of frontline tyrosine kinase inhibitor (TKI) therapy in chronic‐phase chronic myeloid leukemia: The choice of the right TKI for the right patient

Eda Nuhoğlu Kantarcı, Ece Tolgay, Ahmet Emre Eşkazan

In an era when tyrosine kinase inhibitors are gaining acceptance in the treatment scene of chronic‐phase chronic myeloid leukemia, this editorial focuses on the search for the optimal patient‐based frontline treatment option while evaluating a recent study by Tiribelli and colleagues, which …

tr (code pays fourni par la source)

Retrospective Analysis of Prognostic Factors and Survival in Multiple Myeloma Patients Aged 65 Years or Older at Diagnosis in a Real-Life Setting and a Proposed New Staging System

Ali Tunc, Murad Guliyev, Tuba Özkan Tekin, Selin Küçükyurt et autres

Introduction: The incidence of multiple myeloma (MM) increases with age. Novel agents provide better treatment results. However, adults >65 years of age are often underrepresented in clinical trials making it difficult to assess treatment outcomes in older patients. Appropriate strategies are necessary …

tr (code pays fourni par la source)

Gilteritinib in the management of acute myeloid leukemia: Current evidence and future directions

Eda Nuhoğlu Kantarcı, Ahmet Emre Eşkazan

tr (code pays fourni par la source)

The Compliance of Asthma Patients with Their Medication According to the Gina Guideline

Sadiye Şener Çalışkan, Füsun Erdenen, Nazife ÇELİK, Duygu Şak et autres

Objective: Even though asthma patients receive their treatment under a physician’s follow-up, there are many problems with asthma control and medicine usage due to the patients’ incorrect expression of their symptoms and lack of asthma education. Patients are treated with a higher …